Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

New Therapy Found To Prevent Heart Failure
A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only).
generic viagra online
Protect Yourself From Tick And Mosquito Bites To Prevent Illness
Summer is the peak time for people to be bitten by ticks and mosquitoes, which may carry diseases that can infect humans. The Department of Health tracks cases of these diseases and has noted a recent increase in human cases of Rocky Mountain Spotted Fever and ehrlichiosis, both of which are transmitted through tick bites. TDOH urges Tennesseans to follow commonsense precautions to protect themselves and help reduce the risk of illness. Drugshop to buy zoloft online and other pills.
News of the day
Knowing Me, Myself, And I: What Psychology Can Contribute To Self-Knowledge
How well do you know yourself? It"s a question many of us struggle with, as we try to figure out how close we are to who we actually want to be. In a new report in Perspectives on Psychological Science, a journal of the Association for Psychological Science, psychologist Timothy D. Wilson from the University of Virginia describes theories behind self-knowledge (that is, how people form beliefs about themselves), cites challenges psychologists encounter while studying it, and offers ways we can get to know ourselves a little better.
Mental Health

BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions

BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions. The open-label, single arm trial will be conducted in 60 patients with seborrheic keratosis in Germany and the Netherlands. The objectives of the study are to determine the safety and tolerability of the BL-5010 formulation and to assess its efficacy in completely removing the lesion. In addition, we will assess BL-5010"s efficacy in preserving the cellular structure of the lesion for subsequent histological examination. The study is scheduled to start in June, 2009. Interim results from the first 25 patients are expected in the fourth quarter of 2009. "BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions," stated Morris C. Laster, M.D., CEO of BioLineRx. "We look forward to accelerating development of this novel formulation." About Skin Lesions and Current Removal Methods Clinically diagnosed benign skin lesions are very common and often constitute a cosmetic and sometimes functional annoyance. They tend to be wounded, bleed or become infected. In addition, when located in exposed parts of the body, they present a severe aesthetic problem. Skin lesions are currently removed using destructive methods including cryotherapy (liquid nitrogen) and electro-coagulation (electrical burning) or via surgery. Cryotherapy and electro-coagulation are used for the removal of benign superficial lesions and are often associated with pain and inflammation that can last for several months. Surgical removal is used when histological examination of the lesion is required. It has to be conducted under sterile conditions and requires anesthesia. In addition, the cosmetic outcome of surgical removal is less than desirable. The number of lesion removal procedures and in particular non-surgical procedures has substantially increased in recent years. USA and European market size is estimated at $580 mm per year. About BL-5010 BL-5010 is a novel formulation composed of approved components. BL-5010 offers an alternative to painful, invasive and expensive removal treatments including surgery, cryotherapy or laser treatment. Because the treatment is non-invasive, it poses minimal infection risk and no need for anesthesia or bandaging. BL-5010 is applied topically on the lesion for a few minutes, and causes the lesion to gradually dry out and shed from the skin within 1-3 weeks. In addition, we believe that the unique composition of BL-5010 will allow the preservation of the lesion"s cellular structure, enabling histological examination. BL-5010 is being developed by BioLineRx, Ltd. under a worldwide exclusive license from Innovative Pharmaceutical Concepts, Ltd., a privately held company led by Prof. Pinchas Burstein. BioLineRx


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009